*Also known as VIP152.
ADC, antibody-drug conjugate; CDK, cyclin-dependent kinase; DLBCL, diffuse large B-cell Lymphoma; GCB, germinal center B-cell; IV, intravenous; KSPi, kinesin spindle protein inhibitor; MDS, myelodysplastic syndrome; optCPT, optimized camptothecin; P-TEFb, positive transcription elongation factor B; SMDC, small molecule drug conjugate.

Next-Generation Adc Technology

Bioconjugation Platform

Antibody-drug conjugates (ADCs) are an established therapeutic approach in oncology used to selectively deliver potent cytotoxins directly to tumor cells, with the goal of maximizing toxicity in tumor cells, while minimizing toxicity to healthy cells. The antibody component is designed to selectively bind to a distinct antigen preferentially expressed on tumor cells.
Learn more